BIOLASE Inc. (NASDAQ:BIOL) currently has a daily average trading volume of 9.13M but it saw 7671426 shares traded on Wednesday. With a market cap of 19.95M USDstock’s current market price of $0.41 came rising about 0.82 while comparing to the previous closing price of $0.40. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.25 and as low as $0.21. In the recent trading on the day, stock has struck highest price mark of $0.4279 while lowest mark touched by it was $0.395.
Taking a look at 20-day trading activity of BIOLASE Inc. (BIOL) gives us an average price of $0.4186, while its current price level is -67.44% below from 52-week high level whereas it is 92.89% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.4552 while that of 200 days or SMA-200 reads an average of $0.5174. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.61% during that period while stretching the period over a month that increases to 6.36%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.26 which implies that the stock is in neutral territory.
BIOLASE Inc. (BIOL)’s stock is currently under the radar of 3 analysts who are in consensus at a 12-month price target range of between $1.15 and $2.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $1.15 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $2.00. Average price target assigned by them is $1.63 which highlights an upside potential of 74.85% for the stock over that period. And to attain the median price target of $1.75 assigned by those analysts, stock has to add about 76.57% of value to its current levels.
Data by FactSet Research shows that 3 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 3 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the The Benchmark Company which initiated the stock as “Speculative Buy” in its note to investors issued on June 19, 2019, recommending a price target of $2 for it. WallachBeth issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $4 and $2.50.
Over the week, BIOL’s stock price is moving -3.96% down while it is -9.56% when we observe its performance for the past one month. Year-to-date it is -26.36% down and over the past year, the stock is showing a downside performance of -66.64%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2020, when its quarterly earnings per share (EPS) of -$0.12 beat the consensus estimate of -$0.17 for the same. The company is expected to be releasing its next quarterly report in 11/04/2020, for which analysts forecasted an EPS of -$0.06 while estimate for next year EPS is -$0.3. For BIOL, analysts are forecasting an EPS-growth rate of 31.80% for current year and estimate for EPS growth in next year is 70.00%. In next quarter, company is expected to be making quarterly sales of $10.59 million as analysts are expecting the sales for current fiscal year at $23.89 million and seeing the company making $41.5 million in sales next year. Moreover, analysts are in estimates of $5.56 million for current-quarter revenue.
Currently, BIOLASE Inc.’s total number of outstanding shares is 31.51M with 27.02% of that held by the insiders while 37.78% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -112.90%. Stock’s beta reads 2.13. Stock has a price to sale or P/S ratio amounts to 0.62. Its return on asset (ROA) is -61.00% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Vanguard Total Stock Market Index came shrinking its share ownership by 0.00% in the BIOLASE Inc. (BIOL) decreasing its stake to 1.62% with control over 0.0 shares in the company. As per SEC documents, Vanguard Total Stock Market Index shunned 815,191 of company’s common stock of worth $0.33 million as per recent closing price of the stock. Vanguard Total Stock Market Index is not the only institutional holder which restructured its stake in BIOLASE Inc., as Vanguard Extended Market Index Fu dumped 184,507 shares of worth $75463.0 to bring its holdings to a total of 0.0 shares. In the most recent quarter, Fidelity Extended Market Index Fu came cutting its stake by 0.00% in the company and now holds 34145.0 or 0.07% of the company’s stake having worth of about 13965.0.